Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
51 results about "Arenavirus" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An arenavirus is a negative-sense, single-stranded RNA virus that is a member of the family Arenaviridae. These viruses infect rodents and occasionally humans; arenaviruses have also been discovered which infect snakes. At least eight arenaviruses are known to cause human disease. The diseases derived from arenaviruses range in severity. Aseptic meningitis, a severe human disease that causes inflammation covering the brain and spinal cord, can arise from the lymphocytic choriomeningitis virus (LCMV) infection. Hemorrhagic fever syndromes, including Lassa fever, are derived from infections such as Guanarito virus (GTOV), Junin virus (JUNV), Lassa virus (LASV), Lujo virus (LUJV), Machupo virus (MACV), Sabia virus (SABV), or Whitewater Arroyo virus (WWAV). Arenaviruses are divided into two groups: the Old World and the New World viruses. The differences between these groups are distinguished geographically and genetically. Because of the epidemiological association with rodents, some arenaviruses and bunyaviruses are designated as roboviruses.
Method of preventing virus: cell fusion by inhibiting the function of the fusion initiation region in rna viruses having class i membrane fusogenic envelope proteins
ActiveUS20060280754A1Prevent and inhibit infectionSsRNA viruses negative-senseSsRNA viruses positive-senseCell membraneDisease cause
The present invention relates to a method of preventing or inhibiting viral infection of a cell and / or fusion between the envelope of a virus and the membranes of a cell targeted by the virus (thereby preventing delivery of the viral genome into the cell cytoplasm, a step required for. viral infection). The present invention particularly relates to the families of RNA viruses, including the arenaviruses, coronaviruses, filoviruses, orthomyxoviruses, paramyxoviruses, and retroviruses, having Class I membrane fusion proteins as the fusion proteins that mediate this fusion process. The present invention provides for a method of identifying a conserved motif or domain called the fusion initiation region (FIR) in these viruses. The present invention further provides for methods of preventing infection by such viruses, by interfering with their FIR. The present invention further provides for methods of treatment and prophylaxis of diseases induced by such viruses.
Owner:TULANE EDUCATIONAL FUND THE ADMINISTRATORS OF THE
Replication-defective arenavirus vectors
ActiveUS20100297172A1Enhance protein expressionHigh expressionAntibacterial agentsSsRNA viruses negative-senseAntigenDisease
The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III. The modified arenaviruses are useful as vaccines and therapeutic agents for a variety of diseases.
Owner:UNIV ZURICH
Replication-defective arenavirus vectors
Owner:UNIV ZURICH
Tri-segmented arenaviruses as vaccine vectors
ActiveUS20170319673A1High genetic stabilitySsRNA viruses negative-senseVectorsGenomic SegmentDisease
The present application relates to arenaviruses with rearrangements of their open reading frames (“ORF”) in their genomes. In particular, described herein is a modified arenavirus genomic segment, wherein the arenavirus genomic segment is engineered to carry a viral ORF in a position other than the wild-type position of the ORF. Also described herein are trisegmented arenavirus particles comprising one L segment and two S segments or two L segments and one S segment. The arenavirus, described herein may be suitable for vaccines and / or treatment of diseases and / or for the use in immunotherapies.
Owner:UNIVERSITY OF GENEVA
Degenerate primer for detecting virus belonging to virus family Arenaviruses and RT-PCR detection method
InactiveCN103224999AReduce degeneracyRaise the annealing temperatureMicrobiological testing/measurementDNA/RNA fragmentationLymphocytic choriomeningitis virus infectionFamily Arenaviridae
The invention discloses a degenerate primer for detecting virus belonging to the virus family Arenaviruses and a RT-PCR detection method. The degenerate primer can sensitively detect the virus belonging to the virus family Arenaviridae, and is a universal primer which is specific for the virus belonging to the virus family Arenaviridae, and can be used for detecting lymphocytic choriomeningitis virus which is widely distributed, and also can be used for detecting epidemic strains of other Arenaviruses, thereby preventing foreign epidemic strains from affecting our country, and the primer also can be used for detecting unknown viruses which is homologous to the expansion gene, thereby discovering new virus. Because a codehop primer design method is used, the degeneracy of the primer is reduced and the primer annealing temperature is increased simultaneously, thereby improving the singularity of PCR reaction of the designed degenerate primer.
Owner:中华人民共和国大榭出入境检验检疫局
Arenavirus particles as cancer vaccines
ActiveUS20180344830A1Reduce distractionsViral antigen ingredientsCancer antigen ingredientsDiseaseNucleotide
The present application relates generally to genetically modified arenaviruses that are suitable vaccines against neoplastic diseases, such as cancer. The arenaviruses described herein may be suitable for vaccines and / or treatment of neoplastic diseases and / or for the use in immunotherapies. In particular, provided herein are methods and compositions for treating a neoplastic disease by administering a genetically modified arenavirus in combination with an immune checkpoint inhibitor, wherein the arenavirus has been engineered to include a nucleotide sequence encoding a tumor antigen, tumor associated antigen or antigenic fragment thereof.
Owner:HOOKIPA BIOTECH GMBH
Influenza virus inhibiting peptides
Owner:TULANE EDUCATIONAL FUND THE ADMINISTRATORS OF THE
Anti-mycobacterial vaccines
ActiveUS9809801B2SsRNA viruses negative-senseBacterial antigen ingredientsMycobacterium InfectionsAnti mycobacterial
Owner:UNIVERSITY OF GENEVA
Heterocyclic Compounds for the Treatment of Arenavirus
The invention relates to compounds of structural formula Iwherein A, D, and E are independently N or C—R3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R3 or C—R3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R1 is selected from (C6 to C10) aryl, (C2 to C9) heteroaryl, and 5-indolyl, wherein each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is substituted with at least one R4a group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting of
Owner:ARISAN THERAPEUTICS INC
Anti-mycobacterial vaccines
Provided herein are genetically modified arenaviruses suitable as vaccines against mycobacterial infections. The invention also relates to pharmaceutical compositions and methods for the prevention and treatment of mycobacterial infections. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing and treating infections in Mycobacterium tuberculosis.
Owner:UNIVERSITY OF GENEVA
HPV vaccines
ActiveUS10669315B2Reduce severityReduce frequencySsRNA viruses negative-senseViral antigen ingredientsDiseaseHuman papilloma virus infection
Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.
Owner:HOOKIPA BIOTECH GMBH
Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
The present application relates generally to genetically modified arenaviruses that are suitable vaccines against neoplastic diseases, such as cancer. The arenaviruses described herein may be suitable as vaccines and / or for treatment of neoplastic diseases and / or for the use in immunotherapies. In particular, provided herein are methods and compositions for treating a neoplastic disease by administering a genetically modified arenavirus in combination with a chemotherapeutic agent, wherein the arenavirus has been engineered to include a nucleotide sequence encoding a tumor antigen, tumor associated antigen or antigenic fragment thereof.
Owner:HOOKIPA BIOTECH GMBH
Tri-segmented arenaviruses as vaccine vectors
The present application relates to arenaviruses with rearrangements of their open reading frames (“ORF”) in their genomes. In particular, described herein is a modified arenavirus genomic segment, wherein the arenavirus genomic segment is engineered to carry a viral ORF in a position other than the wild-type position of the ORF. Also described herein are trisegmented arenavirus particles comprising one L segment and two S segments or two L segments and one S segment. The arenavirus, described herein may be suitable for vaccines and / or treatment of diseases and / or for the use in immunotherapies.
Owner:UNIVERSITY OF GENEVA
HPV vaccines
ActiveUS20210024584A1SsRNA viruses negative-senseViral antigen ingredientsDiseaseHuman papilloma virus infection
Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses.Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.
Owner:HOOKIPA BIOTECH GMBH
Cross-protective arenavirus vaccines and their method of use
The invention relates to DNA vaccines that target multiple arenavirus agents singly or simultaneously.
Owner:INOVIO PHARMA
Arenavirus particles as cancer vaccines
The present application relates generally to genetically modified arenaviruses that are suitable vaccines against neoplastic diseases, such as cancer. The arenaviruses described herein may be suitable for vaccines and / or treatment of neoplastic diseases and / or for the use in immunotherapies. In particular, provided herein are methods and compositions for treating a neoplastic disease by administering a genetically modified arenavirus in combination with an immune checkpoint inhibitor, wherein the arenavirus has been engineered to include a nucleotide sequence encoding a tumor antigen, tumor associated antigen or antigenic fragment thereof.
Owner:HOOKIPA BIOTECH GMBH
Novel Arenavirus Vaccine
The invention relates to compositions and methods for preventing or treating arenavirus related diseases and disorders through the administration to a subject in need thereof a live-attenuated virus (LAV), wherein the LAV is a codon deoptimized (CD) arenavirus.
Owner:THE SCRIPPS RES INST +1
Novel antiviral compounds and methods using same
The present invention includes bicyclic compounds that are useful in preventing or treating viral infections, such as viral infections caused by a filovirus, arenavirus, rhabdovirus, paramyxovirus, and / or retrovirus. The present invention further includes compositions comprising such compounds, and methods of treating a viral infection in a subject using such compounds.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Pre-or post-exposure treatment for filovirus or arenavirus infection
InactiveUS20110014227A1Avoid infectionRelieve symptomsSsRNA viruses negative-senseOrganic active ingredientsDelivery vehicleViral vector
The compositions and methods of the invention described herein provide pre- or post-exposure treatments against filovirus or arenavirus infection by expressing one or more genes (e.g., two ore more genes) from filoviruses or arenaviruses in a delivery vehicle (e.g., a recombinant viral vector or a liposome).
Owner:TRUSTEES OF BOSTON UNIV +1
Arenavirus vaccine
ActiveUS10342861B2SsRNA viruses negative-senseViral antigen ingredientsAttenuated vaccineDisease cause
The invention relates to compositions and methods for preventing or treating arenavirus related diseases and disorders through the administration to a subject in need thereof a live-attenuated virus (LAV), wherein the LAV is a codon deoptimized (CD) arenavirus.
Owner:THE SCRIPPS RES INST +1
Application of diacerein in preparation of antiviral drugs and treatment of virus infection
ActiveCN111265508AInhibition of replicationInhibitory activityOrganic active ingredientsAntiviralsEnterovirusHepatitis E
The invention discloses application of diacerein in preparation of antiviral drugs and treatment of virus infection, and belongs to new application of diacerein. The experimental results prove that diacerein can be used for effectively inhibiting hepatophilic DNA viruses, retroviruses, enteroviruses, orthomyxoviruses, fibroviruses, reoviruses, arenavirus, hepatitis E viruses, astroviruses, circoviruses, coronaviruses, parvoviruses, adenoviruses, polyomaviruses, herpes viruses, poxviruses, human papillomaviruses, paramyxoviruses, flaviviruses, herpes viruses, alphaviruses and rhabdoviruses.
Owner:CHINA INSPECTION SCI PHARM BEIJING GRP CO LTD
Novel effective antiviral compounds and methods using same
The present invention includes compounds that are useful in preventing or treating viral infections caused by an enveloped RNA virus, such as viral infections caused by a Filovirus, arenavirus, rhabdovirus, paramyxovirus, orthomyxovirus and / or retrovirus. The present invention further includes compositions comprising such compounds, and methods of treating a viral infection in a subject using such compounds.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Application of lacidipine to preparing medicines for treating arenavirus infection
ActiveCN106511343AImprove securityAvoid infectionOrganic active ingredientsAntiviralsNon toxicityLacidipine
The invention provides application of lacidipine to preparing medicines for treating arenavirus infection, and belongs to the field of medicines. The application has the advantages that invasion of arenavirus into host cells can be effectively inhibited by the lacidipine in non-toxicity ranges, and accordingly virus infection due to the arenavirus can be effectively prevented and treated; the lacidipine is excellent in safety, further can be developed to obtain the medicines for treating or preventing the arenavirus infection and has a broad application prospect; the lacidipine further can be applied to preparing medicines for treating virus infection mediated by arenavirus envelope glycoprotein compounds and can act on the arenavirus envelope glycoprotein compounds, and accordingly the virus infection mediated by the arenavirus envelope glycoprotein compounds can be effectively inhibited; all different types of virus infection mediated by the arenavirus envelope glycoprotein compounds can be effectively treated and prevented by the lacidipine.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Pre-or post-exposure treatment for filovirus or arenavirus infection
Owner:TRUSTEES OF BOSTON UNIV +1
Application of bergamottin and/or casticin and product applying same
ActiveCN109864988APrevent and/or treat infectionGood effectAntiviralsHeterocyclic compound active ingredientsBULK ACTIVE INGREDIENTViral infection
The invention relates to the technical field of medicines, and particularly provides application of bergamottin and / or casticin and a product applying the same. The invention provides application of the bergamottin and / or casticin in preparation of a product for preventing and / or treating Arenaviridae virus infection. The bergamottin and casticin are both traditional Chinese medicine monomer smallmolecule compounds, can effectively inhibit the infection of cells by Arenaviridae virus in a non-toxic range, and fill the blank of lack of Arenaviridae virus infection treatment at present. Products prepared by adopting the bergamottin and / or casticin as active ingredients comprise medicines and functional foods, and have good effects on prevention and treatment of arenavirus infection.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Application of dabrafenib and/or medicinal derivative thereof in preparation of anti-arenavirus drug
ActiveCN111973598AStrong anti-arenavirus effectOrganic active ingredientsAntiviralsDabrafenibPharmaceutical drug
The invention provides an application of dabrafenib and / or a medicinal derivative thereof in preparation of an anti-arenavirus drug. By detecting the cytotoxicity of the dabrafenib on Vero cells and BHK-21 cells and the antiviral activity of the dabrafenib on arenavirus, it is indicated that the dabrafenib shows a relatively high arenavirus resisting effect on the cellular level, and a new direction is provided for prevention and treatment of arenavirus infectious diseases.
Owner:CANVEST WUHAN BIOTECH
Compounds for the treatment of arenavirus infection
Compounds as exemplified by compound A are useful in the treatment of arenavirus infections and viral infections mediated by arenavirus glycoproteins.
Owner:阿里桑治疗药物公司
Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
The present application relates generally to genetically modified arenaviruses that are suitable vaccines against neoplastic diseases, such as cancer. The arenaviruses described herein may be suitableas vaccines and / or for treatment of neoplastic diseases and / or for the use in immunotherapies. In particular, provided herein are methods and compositions for treating a neoplastic disease by administering a genetically modified arenavirus in combination with a chemotherapeutic agent, wherein the arenavirus has been engineered to include a nucleotide sequence encoding a tumor antigen, tumor associated antigen or antigenic fragment thereof.
Owner:HOOKIPA BIOTECH GMBH
Heterocyclic compounds for the treatment of arenavirus
The invention relates to compounds of structural formula Iwherein A, D, and E are independently N or C—R3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R3 or C—R3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R1 is selected from (C6 to C10) aryl, (C2 to C9) heteroaryl, and 5-indolyl, wherein each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is substituted with at least one R4a group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting of
Owner:ARISAN THERAPEUTICS INC
Use of diacerein in preparing antiviral drugs and treating viral infections
ActiveCN111265508BInhibition of replicationInhibitory activityOrganic active ingredientsAntiviralsHuman papillomavirusHepadnavirus
The "Use of Diacerein in the Preparation of Antiviral Drugs and Treatment of Viral Infections" of the present invention belongs to the new application of Diacerein. Experiments have proved that Diacerein can effectively inhibit hepadnaviruses, retroviruses, intestinal Viruses, Orthomyxoviruses, Filoviruses, Reoviruses, Arenaviruses, Hepatitis Eviruses, Astroviruses, Orbiviruses, Coronaviruses, Parvoviruses, Adenoviruses, Polyomaviruses, Herpesviruses, Poxviruses , human papillomavirus, paramyxovirus, flavivirus, herpesvirus, alphavirus, rhabdovirus.
Owner:CHINA INSPECTION SCI PHARM BEIJING GRP CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com